Statement By Merck & Co., Inc., In Response To The FDA's Update Regarding A Safety Review On Bisphosphonates Including ... (Medical News Today)
The FDA announced its update on the safety review of bisphosphonates, including FOSAMAX , that found no clear association between overall bisphosphonate exposure and the rate of serious or non serious atrial fibrillation. Increasing dose or duration of bisphosphonate therapy was also not associated with an increased rate of atrial fibrillation.

Gravy or Turkey From the FDA? (The Motley Fool)
These drugmakers should be made aware of their fate over the next few weeks.